GT Biopharma (GTBP) Amortizatization of Intangibles (2010 - 2020)
GT Biopharma (GTBP) posted quarterly Amortizatization of Intangibles of $317000.0 for Q4 2020, up 487.04% year-over-year from $54000.0 in Q1 2020, and up 31800.0% quarter-over-quarter from -$1000.0 in Q3 2020.
GT Biopharma (GTBP) Amortizatization of Intangibles (2010 - 2020) Analysis & Trends
GT Biopharma (GTBP) has reported Amortizatization of Intangibles for 11 consecutive years, with $317000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Amortizatization of Intangibles rose 487.04% year-over-year to $317000.0; the TTM figure through Sep 2021 stood at $317000.0 (up 487.04% YoY), while the FY2020 annual figure was $317000.0, down 37.23% from the prior year.
- Amortizatization of Intangibles rose to $317000.0 in Q4 2020 per GTBP's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $4.2 million in Q2 2018 and bottomed at -$1000.0 in Q3 2020.
- Historically, Amortizatization of Intangibles has averaged $910315.8 across 5 years, with a median of $562000.0 in 2017.
- Annual changes were most pronounced in 2018 — Amortizatization of Intangibles surged 645.55% — and 2020, when it sank 100.83%.
- GT Biopharma's Amortizatization of Intangibles stood at $1.3 million in 2016, then tumbled by 90.33% to $123000.0 in 2017, then soared by 588.62% to $847000.0 in 2018, then sank by 93.62% to $54000.0 in 2019, then surged by 487.04% to $317000.0 in 2020.
- Business Quant data shows GTBP's Amortizatization of Intangibles at $317000.0 in Q4 2020, -$1000.0 in Q3 2020, and $1000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 317,000.00 |
| Dec 31, 2020 | 317,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Jun 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 1,000.00 |
| Dec 31, 2019 | 54,000.00 |
| Dec 31, 2019 | 54,000.00 |
| Sep 30, 2019 | 120,000.00 |
| Sep 30, 2019 | 120,000.00 |
| Jun 30, 2019 | 168,000.00 |
| Jun 30, 2019 | 168,000.00 |
| Mar 31, 2019 | 163,000.00 |
| Mar 31, 2019 | 163,000.00 |
| Dec 31, 2018 | 847,000.00 |
| Dec 31, 2018 | 847,000.00 |
| Sep 30, 2018 | 961,000.00 |
| Sep 30, 2018 | 961,000.00 |
| Jun 30, 2018 | 4.19 Mn |
| Jun 30, 2018 | 4.19 Mn |